Showing results (91-100 of 144) with videos related to

Sort By:
Pageof 15
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 1999
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort StudyS Bassetti, M Battegay, H Furrer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1995
Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the human immunodeficiency virusM Opravil, M Pechère, A Lazzarin, et al.
Journal of Internal Medicine|February 20, 2007
HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapyJ A C Sterne, M May, H C Bucher, et al.
AIDS (London, England)|November 4, 2000
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort StudyO T Rutschmann, P L Vernazza, H C Bucher, et al.
Lancet (London, England)|October 31, 2001
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort StudyJ Fellay, K Boubaker, B Ledergerber, et al.
Pageof 15